Get Live Data
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. AVO.L Share Price
  4. AVO.L Share Regulatory News
  5. Director Dealing

Pin to quick picksAVO.L Regulatory News (AVO)

AVO.L Information
  • There is currently no data for AVO

Director Dealing

26 Apr 2013 12:21

RNS Number : 3522D
Advanced Oncotherapy PLC
26 April 2013
 



26 April 2013

 

ADVANCED ONCOTHERAPY Plc

("Advanced Oncotherapy" or "the Company")

 

Director Dealing

 

Advanced Oncotherapy (AIM: AVO) announces that on 25 April 2013, Tim Lebus, Non-Executive Director, purchased two tranches of ordinary shares of 1 pence each in the share capital of the Company ("Ordinary Shares"), the first tranche of 750,000 Ordinary Shares at a price of 1.56 pence per Ordinary Share. The second tranche of 213,000 Ordinary Shares was purchased at a price of 1.545 pence per Ordinary Share.

 

Following this purchase, Tim Lebus now holds 963,000 Ordinary Shares, representing approximately 0.37 per cent. of the issued share capital of Advanced Oncotherapy.

 

For further information, please visit www.advancedoncotherapy.comor contact:

 

Michael Sinclair,

Chief Executive

Sandy Jamieson

Jon Levinson

Simon Hudson

Advanced

Oncotherapy Plc

Libertas Capital

Corporate Finance Ltd

Peterhouse

Corporate Finance

Tavistock Communications

(NOMAD & Joint Broker)

(Joint Broker)

(Financial PR & IR)

+44 20 3617 8739

+44 20 7569 9650

+44 20 7469 0930

+44 20 7920 3150

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBBGDSGDDBGXL
12345678910
Date   Source Headline
30th Oct 20205:00 pmRNSTotal Voting Rights
26th Oct 20207:00 amRNSEquity fundraise of c.£7.7m
23rd Oct 20202:25 pmEQSHardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy: Progress towards commissioning of first LIGHT
19th Oct 20207:00 amRNSInvestor Day Update
8th Oct 20202:06 pmRNSSecond Price Monitoring Extn
8th Oct 20202:00 pmRNSPrice Monitoring Extension
7th Oct 202010:50 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Progress towards commissioning of first LIGHT
6th Oct 20207:00 amRNSReplacement: Grant of LTIP Options
5th Oct 20207:01 amRNSNotice of Investor Day
5th Oct 20207:00 amRNSGrant of LTIP Options
29th Sep 20207:00 amRNSDirectorate Appointment
29th Sep 20207:00 amRNSInterim Results
8th Sep 20207:00 amRNSTechnical Development Update
7th Sep 20207:00 amRNSAppointment of Joint Broker
21st Aug 20207:00 amRNSDraw down from Nerano Pharma debt facility
18th Aug 20204:30 pmRNSDirector/PDMR Shareholding
29th Jul 20202:52 pmRNSResult of AGM and Directorate Changes
2nd Jul 20207:15 amEQSHardman & Co Research : Advanced Oncotherapy (AVO): End-goal fast approaching
29th Jun 20207:01 amRNSFinal Results for the year ended 31 December 2019
29th Jun 20207:00 amRNSStrategic funding partnership and debt facility
17th Jun 20207:00 amRNSHolding(s) in Company
8th Jun 20207:00 amRNSDirectorate Changes and Notice of Results
3rd Jun 20205:30 pmRNSHolding(s) in Company
29th May 20205:00 pmRNSTotal Voting Rights
20th May 20204:30 pmRNSHolding(s) in Company
11th May 20206:01 pmRNSResult of General Meeting, Additional Subscription
21st Apr 20207:00 amRNSNotice of GM and Posting of Circular
9th Apr 20207:30 amRNSFurther re Subscription and Issue of Equity
9th Apr 20207:00 amRNSProposed Subscription to raise c.£15 million
26th Feb 20203:40 pmEQSHardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy (AVO): Confidence in LIGHT gaining momentum
20th Feb 20207:00 amRNSUHB and AVO to collaborate over LIGHT system
20th Feb 20207:00 amRNSUHB and AVO to collaborate over LIGHT system
17th Feb 202011:45 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Confidence in LIGHT gaining momentum
17th Feb 20207:00 amRNSPurchase of a LIGHT proton therapy system
11th Feb 20207:00 amRNSPartnership with The London Clinic
4th Dec 20197:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Proving the accuracy and superiority of minibeams
4th Dec 20197:00 amRNSTwo-Year Collaborative Research Study
3rd Dec 20195:45 pmRNSHolding(s) in Company
29th Nov 20195:00 pmRNSTotal Voting Rights
28th Nov 201910:15 amRNSHolding(s) in Company
20th Nov 20197:00 amRNSSubscription to raise c.GBP 2.7 million
11th Nov 20199:11 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): FLASH benefits from new US reimbursement
6th Nov 20193:35 pmRNSTotal Voting Rights
10th Oct 20197:00 amRNSChange of Broker
30th Sep 20195:15 pmRNSTotal Voting Rights
30th Sep 20197:00 amRNSFurther re funding for first LIGHT system
30th Sep 20197:00 amRNSHalf-year Report
9th Sep 20194:48 pmRNSExercise of Warrants and Issue of Equity
30th Aug 20195:00 pmRNSTotal Voting Rights
29th Aug 20192:06 pmRNSHolding(s) in Company
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
POL
POL.L
LSE
0.00%
MMX
MMX.L
LSE
0.00%
FTC
Filtronic
LSE
0.64%
CMHY
CMHY.L
LSE
0.00%
MIX
Mobeus I&g
LSE
0.00%
Trending
GST
GSTechnologies
LSE
0.00%
SBDS
Silver Bullet
LSE
-66.00%
OMI
Orosur Mining
LSE
6.33%
RCGH
Rc365 Holding
LSE
111.43%
NANO
Nanoco
LSE
-3.70%